Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0409)
Name
Fer-1 analogue 39
Drug Type
Small molecule
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Neuroblastoma ICD-11: 2D50
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model IMR-32 cells Neuroblastoma Homo sapiens CVCL_0346
In Vivo Model
All mice treated with iron sulfate received an intraperitoneal injection of 300 mg/kg body weight FeSO4·7H2O dissolved in sterile 0.9% NaCl or vehicle (0.9% NaCl). The injection volume was 200 uL/20 g body weight. Vehicle solution (2% DMSO) or compound was administered at a concentration of 2 mM (in 0.9% NaCl containing 2% DMSO; 200 uL/20 g body weight) by intravenous injection 15 min before IP injection with FeSO4·7H2O. Two hours after iron sulfate injection, mice were anesthetized with isoflurane and blood was sampled.

    Click to Show/Hide
Response regulation The study report the synthesis of a more stable and readily soluble series of Fer-1 analogues that potently inhibit ferroptosis. The most promising compounds (37, 38, and 39) showed an improved protection compared to Fer-1 against multiorgan injury and neuroblastoma in mice.
References
Ref 1 Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. J Med Chem. 2018 Nov 21;61(22):10126-10140. doi: 10.1021/acs.jmedchem.8b01299. Epub 2018 Nov 6.